Acute myeloid leukemia, NOS

Name
Acute myeloid leukemia, NOS
ICD-O-1 Morphology
9861/3
Effective 1978 - 1991
ICD-O-2 Morphology
9861/3
Effective 1992 - 2000
ICD-O-3 Morphology
9861/3
Effective 2001 and later
Reportable
for cases diagnosed 1978 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)

Help me code for diagnosis year :

Grade
Code grade specified by pathologist. If no grade specified, code 9
Module Rule
See abstractor notes
Alternate Names
Acute granulocytic leukemia
Acute myelocytic leukemia
Acute myeloid leukemia, NOS
Acute myeloid leukemia with cytoplasmic nucleophosmin (NPMc + AML)
Acute myeloid leukemia with mutated CEBPA
Acute myeloid leukemia with mutated NPM1
AML
Definition
Cases of AML that do not fulfill the criteria for AML with recurrent genetic abnormalities, AML with multilineage dysplasia or AML and MDS, therapy-related fall into this category. The defining criterion for AML is 20% or more blasts in the blood or bone marrow.

This is a cancer of the myeloid line of white blood cells, characterized by the rapid proliferation of abnormal cells which accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age.
Abstractor Notes
Acute myeloid leukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification.

In most cases, NOS histology is only the provisional diagnosis; the physician will run further diagnostic procedures and look for various clinical presentations to identify a more specific disease. Further review of the medical record should be done to look for the tests listed as definitive diagnosis. If no information is found in the medical record, follow-back to the attending physician should be done.

More specific myeloid leukemias include
1. Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1 (9911/3)
2.Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB/MYH11 (9871/3)
3.Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26;2); RPN1-EVI1 (9869/3)
4. Acute myeloid leukemia with maturation (9874/3)
5. Acute myeloid leukemia with minimal differentiation (9872/3)
6. Acute myeloid leukemia with mutated CEBPA (9861/3)
7. Acute myeloid leukemia with mutated NPM1 (9861/3)
8. Acute myeloid leukemia with myelodysplasia-related changes (9895/3)
9. Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214 (9865/3)
10. Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 (9896/3)
11. Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL (9897/3)
12. Acute myeloid leukemia without maturation (9873/3)
13. Myeloid leukemia associated with Down syndrome (9898/3)
14. Myeloid neoplasm with PDGFRB arrangement (9966/3)

When a more specific diagnosis is identified, the histology should be changed to the more specific neoplasm name and code. See the histology tables for more information on NOS and more specific histologies.

This code is also used for AML with mutated NPM1 and AML with mutated CEBPA. Note in your abstract whether this is AML, NOS or AML with mutated NPM1 or DEBPA. If the diagnosis is either of these specific AML the histology code should not be changed.

If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Immunophenotyping
Genetics Data
CEBPA
FLT3-ITD
NPM1
Immunophenotyping
CD11b
CD13
CD14
CD33 MPO
CD34
CD68
Varies by subclassification
Treatments
Chemotherapy
Stem cell transplant
Transformations to
None
Same Primaries
Corresponding ICD-9 Codes
205.0 Acute myeloid leukemia
Corresponding ICD-10 Codes
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (effective October 1, 2015 U.S. only)
C92.0 Acute myeloblastic leukemia
Signs and Symptoms
Easy bruising or bleeding
Fatigue
Fever
Petechiae
Shortness of breath
Weakness
Weight loss or loss of appetite
Diagnostic Exams
Complete blood count (CBC)
CT (CAT) scan
Cytogenetic analysis
Reverse transcription-polymerase chain reaction test (RT-PCR)
Recurrence and Metastases
None
Epidemiology and Mortality
None